About us

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Our major focus is on bacterial diseases targeting animal health, human food safety and zoonotic diseases.

The company is specialized on glycoengineering technologies to develop novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Our platform technology provides a tool to develop a strong pipeline of novel, cost-efficient vaccine products.
Our first vaccines target the medical areas of human Campylobacter infections (prevention of human food poisoning) and porcine Actinobacillus pleuropneumoniae infections (prevention of economic loss during food production).

The enormous economic potential of novel vaccines lays the ground for a successful development of the company. Malcisbo`s team is determined to build a major player in providing innovative vaccines for unmet medical  and industrial needs.

We employ a strong multi-disciplinary team of 7 people exhibiting complementary skills in different areas. The company maintains an extensive international network.

Malcisbo, domiciled in Schlieren, Switzerland, was incorporated in May 2010 as a spin-off from the  Swiss Federal Institute of Technology Zurich (ETH Zurich).

Photos from us

 |<  <  1 - 2 >  >|
IMG_7156_small IMG_9268_small IMG_9269_small

Latest News

  • 26 November 2018

    VetBioNet grant

    Malcisbo wins a grant to perform an APP challenge trial in a BLS3 facility.

  • 25 January 2017

    Malcisbo has been selected as emerging company to present at the Animal Health Investment Forum in London (Feb 2017)

  • 21 December 2016

    Malcisbo participates in a CTI-funded research project on the development of a vaccine against APP.